ReviewFrontiers in oncology2026
Advancing systemic therapy for biliary tract cancer: current strategies and emerging paradigms.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most patients diagnosed with biliary tract cancer (BTC) present with advanced, often unresectable disease. Additionally, a significant proportion of those who undergo curative intent resection experience disease recurrence. The aggressive nature and poor prognosis of BTC underscore the urgent need for effective and safe systemic therapies. For many years, progress in the therapy of BTC was limited. However, advances in our understanding of the molecular biology of BTC created a paradigm shift in its treatment. Novel therapies, particularly personalized approaches based on genomic profiling and use of targeted treatments, have significantly transformed the management algorithm for advanced BTC. These advances represented a major step forward in improving outcomes for patients with this very challenging malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.